Helus Reports Positive Phase 3 Readout for Deuterated Psilocin as an Adjunctive Depression Treatment
Summary
Helus Pharma reported that HLP003, a deuterated psilocin analog, met the primary endpoint in its first Phase 3 study as an adjunctive treatment for major depressive disorder. The APPROACH trial enrolled adults who had responded inadequately to antidepressants and gave participants two 16 mg doses of HLP003 or placebo, three weeks apart. A second pivotal study, EMBRACE, is still enrolling, with topline results expected in the fourth quarter of 2027. Some participants are also being followed in EXTEND, a long-term study offering open-label dosing or re-dosing to people who did not respond or who relapsed. The supplied material does not provide detailed efficacy or safety results.